文献速递结核与非结核分枝杆菌医院感染防控

每周利福喷丁联合异烟肼预防中国矽肺患者结核病的疗效与安全性

Efficacy and safety of weekly rifapentine and isoniazid for tuberculosis prevention in Chinese silicosis patients: a randomized controlled trial.
PubMed 文献 · Clin Microbiol Infect · 2020-06-15

该随机对照试验纳入513例无HIV感染的男性矽肺患者,1:1分配至3个月每周一次利福喷丁/异烟肼直接面视下治疗组或未治疗观察组,随访37个月。意向性分析中活动性结核累积率分别为3.5%和7.3%(log rank P=0.055),符合方案分析为0.7%和7.3%(log rank P=0.01)。不良反应发生率高,完成率仅54.7%。

要点

  • 3RPT/INH方案在完成治疗者中可降低活动性结核风险。
  • 不良反应发生率高(70.4%),完成率仅54.7%,需谨慎使用。
  • 疗效受依从性影响,无论是否筛查潜伏结核感染均可获益。

核心结论

  • 每周利福喷丁/异烟肼预防可减少中国矽肺患者活动性结核,但依从性差会降低疗效。
  • 因不良反应发生率高,该方案须谨慎使用。

研究设计与样本

  • 随机对照试验,纳入513例18至65岁无HIV感染的男性矽肺患者,1:1分配至3RPT/INH组(n=254)或未治疗观察组(n=259),随访37个月。

主要发现

  • 意向性分析中活动性结核累积率3RPT/INH组3.5%(9/254),观察组7.3%(19/259),log rank P=0.055。
  • 符合方案分析中活动性结核累积率3RPT/INH组0.7%(1/139),观察组7.3%(19/259),log rank P=0.01。
  • 不良反应发生率70.4%,3或4级不良反应7.9%,完成率54.7%(139/254)。

关键数值与推荐

  • 3RPT/INH方案为3个月每周一次利福喷丁联合异烟肼,直接面视下服药。
  • 纳入标准为无HIV感染的男性矽肺患者,年龄18至65岁,伴或不伴潜伏结核感染。

临床怎么用

  • 对矽肺患者可考虑3RPT/INH预防结核,但需加强不良反应监测和依从性管理。
  • 治疗前应评估肝毒性等风险,并告知患者可能出现类流感样反应。

局限性

  • 意向性分析中活动性结核率差异无统计学意义(P=0.055)。
  • 完成率低(54.7%),可能影响疗效评估。
  • 仅纳入男性矽肺患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim was to evaluate the efficacy, safety and completion rate of 3-month, once-weekly rifapentine and isoniazid for tuberculosis (TB) prevention among Chinese silicosis patients. METHODS: Male silicosis patients without human immunodeficiency virus infection, aged 18 years to 65 years, with or without latent TB infection, were randomized 1:1 to receive rifapentine/isoniazid under direct observation (3RPT/INH group) or were untreated (observation group). Active TB incidence was compared between the two groups with 37 months of follow-up. Safety profile and complete rates were evaluated. RESULTS: A total of 1227 adults with silicosis were screened; 513 eligible participants were enrolled and assigned to 3RPT/INH (n = 254) vs. observation (n = 259). Twenty-eight participants were diagnosed with active TB, and 9 and 19 in the 3RPT/INH group and observation groups, respectively. In the intention-to-treat analysis, the cumulative active TB rate was 3.5% (9/254) in the 3RPT/INH group and 7.3% (19/259) in the observation group (log rank p 0.055). On per protocol analysis, the cumulative active TB rates were 0.7% (1/139) and 7.3% (19/259), respectively (log rank p 0.01). Owing to an unexpected high frequency of adverse events (70.4%) and Grade 3 or 4 AEs (7.9%), the completion rate of the 3RPT/INH regimen was 54.7% (139/254). Twenty-six (10.8%) participants had flu-like systemic drug reactions; five (2.1%) experienced hepatotoxicity. DISCUSSION: Weekly rifapentine/isoniazid prophylaxis prevented active TB among Chinese people with silicosis when taken, irrespective of LTBI screening; efficacy was reduced by lack of compliance. The regimen must be used with caution because of the high rates of adverse effects. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov number: NCT02430259.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Ruan QL, Huang XT, Yang QL, et al. Efficacy and safety of weekly rifapentine and isoniazid for tuberculosis prevention in Chinese silicosis patients: a randomized controlled trial. Clin Microbiol Infect. 2020. PMID: 32553881. doi:10.1016/j.cmi.2020.06.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。